Compare Diamondback Energy Inc (FANG) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Medpace Holdings Inc — how do they compare? Diamondback Energy Inc trades at $192.03 (market cap $53.67B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Diamondback Energy Inc is far larger — about 3.2× Medpace Holdings Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Medpace Holdings Inc for 14 Days on average.
| FANG | MEDP | |
|---|---|---|
Market Cap | $53.67B | $16.82B |
Volume | 2,250,644 | 223,093 |
Sector | Energy | Health |
52-Week High | $213.69 | $630.19 |
52-Week Low | $137.29 | $393.42 |
Typical Hold Time | 69 Days | 14 Days |
Enterprise Value | $65.83B | $16.44B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.13, up 4.2% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains solid cash flow from operations. Revenue growth is robust, with 2025 revenue reaching $14.93 billion, though net income margins have compressed. A dividend of $1.10 is scheduled for August 2026, and institutional interest remains high.
The outlook is positive with a consensus price target of $231.77, implying 20% upside. Risks include volatile oil prices and insider selling, but strong Permian Basin positioning and efficient operations support growth. Earnings on November 2, 2026, will be critical for near-term momentum.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
